GlassScriptPhysician profile
Sukanthini Subbiah
NPI 1578627394
$12,277.98
in general payments reported to CMS, 2019-2025
14 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2022: $99.39 · 2023: $165 · 2024: $12K · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,600 · Food and Beverage: $1,303 · Travel and Lodging: $1,141 · Education: $20.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,600.00 |
| Food and Beverage | $1,303.06 |
| Travel and Lodging | $1,140.99 |
| Education | $20.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $11,577.86 | 2022-2025 | |
| Abbvie INC. | $149.92 | 2024-2025 | |
| Kite Pharma, INC. | $116.41 | 2024 | |
| Celgene Corporation | $92.19 | 2024 | |
| Genentech USA, INC. | $71.63 | 2024 | |
| Beone Medicines USA, INC. | $60.61 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $57.14 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $52.83 | 2025 | Hemangeol |
| Astrazeneca Pharmaceuticals LP | $21.99 | 2023 | Enhertu |
| Genmab U.S., INC. | $20.50 | 2025 | Epkinly |
| Janssen Biotech, INC. | $17.43 | 2019 | |
| Exelixis INC. | $14.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.71 | 2019 | |
| Amgen INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukanthini Subbiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.